![](https://investorshub.advfn.com/uicon/545513.png?cb=1506116101)
Monday, May 02, 2022 4:59:46 PM
661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
Recent LYEL News
- Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology • GlobeNewswire Inc. • 06/26/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:07:01 PM
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference • GlobeNewswire Inc. • 06/03/2024 08:05:00 PM
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 12:12:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 12:06:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 12:03:04 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:07:21 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Lyell Immunopharma Announces Participation in March Investor Conferences • GlobeNewswire Inc. • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:24:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:22:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:19:16 AM
- Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:55:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:54:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:52:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:26:02 PM
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:14:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:08:41 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing • GlobeNewswire Inc. • 10/31/2023 01:00:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM